Q2 2025 ImmuCell Corp Earnings Call Transcript
Key Points
- ImmuCell Corp (ICCC) completed its investment to increase production capacity for the First Defense product line, supporting $30 million or more in revenue per year.
- Product sales during the second quarter of 2025 increased by 18% compared to the same period in 2024, and by 22% over the trailing 12-month period.
- Gross margin as a percentage of product sales improved significantly, reaching 44% in the second quarter of 2025 compared to 22% in the second quarter of 2024.
- The company successfully eliminated its backlog of orders and rebuilt inventory and distribution channels.
- ImmuCell Corp (ICCC) refinanced a portion of its bank debt, reducing interest rates and avoiding large balloon payments due in 2026.
- The completion of the production capacity expansion took longer than planned due to contamination events and other challenges.
- There is an anticipated softening in sales during the second half of 2025 as the inventory rebuild is not expected to repeat.
- The FDA approval for the Retain product is delayed due to unresolved inspection observations at a contract manufacturing organization.
- ImmuCell Corp (ICCC) faces challenges in regaining customers lost during the period of short product supply.
- The company has inventory for the Retain product with a short shelf life, which will be used in investigational studies rather than generating sales.
Good morning and welcome to EUL Corporation reports second quarter ended June 30, 2025 unauudited financial results conference call. (Operator Instructions) Please note that this event is being recorded. I would now like to turn the conference over to Joe Diaz of Lili Partners. Please go ahead.
Thank you and good morning to everyone. As the conference call. Operator indicated my name is Joe Diaz. I'm with Liam Partners. We're the investor relations consulting firm for Eusel.
Thank you again for all of us for joining us today to discuss the unauudited financial results for the 2nd quarter ended June 30, 2025. Listeners are reminded and cautioned that statements made by management during the course of this call include forward-looking statements which include any statement that refers to future events or expected future results or predictions about steps the company plans to take in the future.
These statements are not guarantees of performance and are subject to risks and uncertainties that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
